Pernod Ricard (EPA: RI) records organic net sales decline of more than 2.0% year-on-year in its Q1 FY2027 trading update (August–October 2026, release ~early November 2026), confirmed by Pernod Ricard press release or Bloomberg by November 15, 2026
The premium spirits industry faces structural headwinds in 2026: GLP-1 drugs (Ozempic/Wegovy) dampen alcohol demand, post-COVID normalization pressures premium pricing, and China remains a growth drag. Pernod Ricard reported several consecutive quarters of negative organic growth in FY2025/26. The analogy to Rémy Cointreau (open Cassandra forecast: organic decline H1 FY2026/27) supports the view. No Polymarket market available; own estimate based on industry structure and historical quarterly trends: ~55%.
55%